Crotonylation sensitizes IAPi-induced disruption of latent HIV by enhancing p100 cleavage into p52

Highlights
- Crotonylation enhances IAPi (AZD5582)-induced HIV latency reversal
- Crotonylation augments the p100 cleavage into p52
- TRIM27 is involved in the enhanced p100 cleavage
- TRIM27 Knockdown reduced p100/p52 levels and inhibits HIV latency reversal
Article

Crotonylation sensitizes IAPi-induced disruption of latent HIV by enhancing p100 cleavage into p52

Daijiang Li,1 Morgan G. Dewey,1 Li Wang,2 Shane D. Falcinelli,1,3 Lilly M. Wong,1 Yuyang Tang,1 Edward P. Browne,1,3,4 Xian Chen,2 Nancie M. Archin,1,4 David M. Margolis,1,3,4 and Guochun Jiang1,2,5,*

SUMMARY

The eradication of HIV infection is difficult to achieve because of stable viral reservoirs. Here, we show that crotonylation enhances AZD5582-induced noncanonical NF-κB (ncNF-κB) signaling, further augmenting HIV latency reversal in Jurkat and U1 cell line models of latency, HIV latently infected primary CD4+ T cells and resting CD4+ T cells isolated from people living with HIV. Crotonylation upregulated the levels of the active p52 subunit of NF-κB following AZD5582. Biochemical analyses suggest that the ubiquitin E3 ligase TRIM27 is involved in enhanced p100 cleavage to p52. When TRIM27 was depleted, AZD5582-induced HIV latency reversal was reduced. TRIM27 small interfering RNA (siRNA) knockdown reduced both p100 and p52 levels without inhibiting p100 transcription, indicating that TRIM27 not only acts on p100 cleavage but also may impact p100/p52 stability. These observations reveal the complexity of HIV transcriptional machinery, particularly of NF-κB.

INTRODUCTION

Current antiretroviral therapy (ART) effectively inhibits viral replication and slows disease progression but fails to eliminate the extremely stable HIV reservoirs in patients (Chun et al., 1997; Finzi et al., 1997; Wong et al., 1997). Over the past decades, enormous efforts have been made to directly attack latent HIV-1 (HIV) in which HIV latency reversal agents (LRAs) (Archin et al., 2012; Cary et al., 2016; Karn, 2011; Sengupta and Siliciano, 2018) are combined with immune enhancing methods for effective clearance of viral reservoirs. Many LRAs have been tested to target mechanisms of HIV latency, including epigenetic regulators to remodel the chromatin environment at the HIV LTR, protein kinase C agonist (PKCa) to induce activation of canonical NF-κB (cNF-κB) signaling, or bromodomain inhibitor (BETi) to inhibit BRD4 in the TAR/Tat/P-TEFb complex (Archin et al., 2012, 2014; Banerjee et al., 2012; Friedman et al., 2011; Jiang et al., 2007, 2014; Karn, 2011; Karn and Stoltzfus, 2012; Kessing et al., 2017). Among all these LRAs, PKCa has been shown to be the strongest in ex vivo studies (Darcis et al., 2015; Jiang and Dandekar, 2015; Jiang et al., 2015; Laird et al., 2015; Spina et al., 2013). Therefore, several preclinical and pilot clinical studies have been carried out to test their potential clinical relevance (Gutierrez et al., 2016; Marsden et al., 2017). Although PKCa can disrupt latent HIV ex vivo and in a topical skin lesion model of latency in vivo (Jiang et al., 2015, 2019; Sloane et al., 2020), concerns remain regarding side effects from cellular toxicities and immune activation following systemic administration. Alternative strategies for the activation of NF-κB are being pursued.

In addition to the canonical NF-κB (cNF-κB) pathway, other NF-κB subpathways regulate gene transcription via NF-κB DNA binding sites (Wong and Jiang, 2021). These include noncanonical NF-κB (ncNF-κB) and atypical NF-κB pathways (Sun, 2012; Sun and Ley, 2008; Wong and Jiang, 2021). For example, whereas RelA/p50 is released from IκB after IκB phosphorylation and ubiquitination during canonical NF-κB signaling, the activation of ncNF-κB is dependent on the cleavage of p100 into p52 after p100 phosphorylation by NF-κB activating kinase (NIK) (Sun, 2012). Targeting the noncanonical NF-κB pathway has recently been explored for the disruption of HIV latency (Pache et al., 2015). siRNA knockdown identified one essential negative regulator of ncNF-κB, BIRC2/clAP1, as an inhibitor of HIV transcription and promoter of HIV (Pache et al., 2015). When targeted by the inhibitor of apoptosis (IAP) inhibitor small molecules (IAPi, also known as SMAC mimetics), clAP1 auto-ubiquitinates and is degraded by the proteasome. The loss of clAP1 enables NIK to accumulate and phosphorylate p100, leading to cleavage and release of p52.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
the active subunit p52, which translocates to the nucleus to form a transcriptional activator in complex with RelB.

Most recently, it was reported that the induction of ncNF-κB by the IAPi AZD5582 (Hennessy et al., 2013) induced HIV expression in both HIV-infected, ART-suppressed humanized mice and SIV-infected, ART-suppressed macaques (Hennessy et al., 2013; Nixon et al., 2020). Of note, ncNF-κB signaling tends to be slower and the induction of ncNF-κB by IAPi is more selective, inducing only a few hundred genes in contrast to the thousands of host genes modulated by the cNF-κB, MAPK, and calcineurin signaling induced by PKCa (Nixon et al., 2020; Sun, 2017).

In a previous study, we found that protein crotonylation is involved in the transcription of HIV and/or latency reversal, which significantly enhanced canonical NF-κB activation-induced latency reversal compared with other signaling pathways associated with HIV latency (Jiang et al., 2018). In this study, we aimed to understand whether the activation of ncNF-κB can be improved by protein crotonylation to allow accelerated clearance of latent HIV. We found that the treatment with sodium crotonate enhanced HIV transcription from latency induced by IAPi. This was observed in Jurkat HIV latency models, the promonocyte HIV latency model U1 cells, primary CD4+ T cell model of latency and resting CD4+ T cells isolated from ART-suppressed people living with HIV (PLWH). We observed that crotonylation augmented the levels of p52 induced by AZD5582 in the Jurkat model of HIV latency, a crucial step for the activation of the ncNF-κB pathway. As the induction of crotonylation is expected to induce HIV expression via crotonylation mechanisms (Jiang et al., 2018), we further sought to understand this unexpected effect on p52. Proteomic analysis identified TRIM27 as an important target of protein crotonylation in response to crotonate, whereas TRIM27 siRNA knockdown inhibited latency reversal and dampened p100/p52 protein levels. TRIM27 could be involved in HIV transcription through its known interaction with USP7, thereby regulating p100 cleavage to enhance ncNF-κB signaling for latency reversal.

RESULTS

Protein crotonylation sensitizes IAPi-induced disruption of latent HIV in a broad range of HIV latency models

Previously, we showed that the metabolic induction of protein crotonylation in cells supplemented with sodium crotonate (NaCr) reversed HIV latency through increased expression of the crotonyl-CoA–producing enzyme acyl-CoA synthetase short-chain family member 2 (ACSS2). In this setting, the induction of latent HIV was further enhanced by PEP005, a canonical NF-κB activator. To determine if increased crotonylation also augmented ncNF-κB signaling and HIV latency reversal induced by IAPi, we tested the IAPi, AZD5582, in the Jurkat cell line models of latency, 2D10 and J-Lat A1 cells (Figure 1). Consistent with our previous observations (Jiang et al., 2018), crotonylation induction alone reactivated latent HIV with no significant toxicity in the 2D10 (Figures 1A and S1B) and J-Lat A1 cells (Figures 1D and 1E). Importantly, simultaneous induction of protein crotonylation by NaCr and activation of ncNF-κB signaling by AZD5582 synergistically reactivated HIV from latency with no significant toxicity in the 2D10 (Figures 1A and S1B) and J-Lat A1 cells (Figures 1D and 1E). Importantly, simultaneous induction of protein crotonylation by NaCr and activation of ncNF-κB signaling by AZD5582 synergistically reactivated HIV from latency with no toxicity (Figures 1A–1F). A similar synergistic effect was also observed in the J-Lat 10.6 model of latency (Figures S1A and S1B). [Crotonylation enhances AZD5582-induced HIV transcription from latency in J-Lat 10.6 model of HIV latency], related to Figure 1).

To confirm the above observations in cells that were not transformed, we repeated the experiments in a previously reported primary CD4+ T cell model of latency (Bradley et al., 2018). Briefly, CD4+ T cells were isolated from HIV-negative donors and infected with GFP-tagged NL4.3Δ6 HIV. A few days later, GFP + positive cells were sorted by flow cytometry and co-cultured on H80 feeder cells to allow descent into latency. GFP- CD4+ T cells were FACSorted, expanded and allowed to return to a quiescent state. The latency infected population of primary CD4+ T cells was reactivated by anti-CD3/CD28. These cells gradually returned to latency after anti-CD3/CD28 removal (Figure 2A). This primary CD4+ T cell model of latency (CD4+ T cells were from donor E117) was treated with 30 mM NaCr, 100 nM AZD5582, or with a combination of 30 mM NaCr with 100 nM AZD5582 for 24 h (Nixon et al., 2020). A higher dosage of AZD5582 was used to disrupt latent HIV in primary CD4+ T cells (Nixon et al., 2020). We measured GFP by flow cytometry and found that the induction of crotonylation in this model resulted in the induction of expression of latent HIV. Unlike crotonate, in this primary cell model the induction of ncNF-κB activation by AZD5582 alone had limited effects on latency disruption 48 h post-treatment, compared to control treatment. However, the percentage of GFP-positive cells was significantly increased in cells exposed to combination of AZD5582 with crotonate, compared with AZD5582 treatment alone (Figures 2B and 2C) with no
significant induction of toxicity. This was similarly observed in another primary CD4+ T cell model of latency (CD4+ T cells were from donor E47) (Figure 2D–2F). Interestingly, unlike in E117, there was synergistic reactivation between NaCr and AZD5582, although not strong, indicating that the degree of latency reversal enhancement may vary among primary CD4+ T cell models of latency. Taken together, these data indicate that simultaneous crotonylation and ncNF-κB signaling augments the reactivation of latent HIV.

Crotonylation enhances latency reversal elicited by other IAPi

Other IAPis, such as birinapant, have been developed for use in oncology (Condon et al., 2014). We examined the effect of birinapant in combination with crotonate to see whether the synergistic latency reversal induced by crotonate is a specific property of AZD5582 (Figures 3 and S2. [Cellular viability during IAPi treatment in HIV latency models], related to Figure 3). We first compared the latency reversal activity of these two IAPis. In both 2D10 and J-Lat A1 cells, AZD5582 was more effective in latency reversal than Birinapant. Notably, even at 1 nM, AZD5582 was able to induce transcription of HIV compared with control. Surprisingly, in the promonocytic U1 model of latency, IAPi induced little latency reversal, except with a
high concentration of 500 nM (Figure 3A). Next, we compared IAPi latency reversal in combination with crotonate. Here, 10 nM was selected so that roughly comparable latency reversal could be seen in the different cell models. In combination, crotonate was able to increase the latency reversal induced by IAPi, even in the U1 cell model of latency. However, overall, crotonate similarly augmented the effect of AZD5582 and Birinapant (Figure 3B). Therefore, although latency reversal activity differs between IAPis and across HIV latency models, IAPi latency reversal appears broadly enhanced by crotonate.

Further, it has been reported that high concentrations of IAPi may be able to directly induce cell death of HIV + memory CD4+ T cells (Campbell et al., 2018). However, we did not observe cell death in the population of GFP + cells treated with IAPi alone in 2D10 cell model of latency (Figures 4A–4C). Notably, even at high dosages where latency reversal by both compounds reached >50% of the cells, AZD5582 failed to induce Annexin V in GFP + cells. However, an enhancement of Annexin V+ cells was observed in a minority of GFP + cells when treated with birinapant in combination with crotonate. Similarly, no significant induction of apoptosis was observed in the GFP + primary CD4+ T cell model of latency, with either single agent or combination treatment (Figure S3. [Crotonylation and IAPi treatments induce limited apoptosis in the primary CD4+ T cell model of latency], related to Figure 4), suggesting that crotonate may produce subtle differences in the induction of cellular pathways by different IAPis, even when HIV latency reversal effects measured appear similar (Figures 4B and 4C).

**Crotonate enhances IAPi-induced cleavage of p100 into p52**

One of the key steps in the activation of the ncNF-κB signaling pathway is the cleavage of p100 into p52, which occurs after phosphorylation of p100 by NIK. The latter is normally degraded via cIAP1 ubiquitination (Sun, 2017). IAPi such as AZD5582 bind to cIAP1 to induce its auto-ubiquitination and degradation, which allows NIK to accumulate (Figure 5A). This leads to reactivation of latent HIV by induction of p100 cleavage into p52 and ncNF-κB signaling (Nixon et al., 2020). We noted with interest that crotonate was able to...
significantly enhance ncNF-κB-induced latency reversal in all models (Figures 1 and 2). We therefore sought to explore the possibility that crotonylation enhanced ncNF-κB signaling and reactivation of latent HIV via mechanisms beyond the known effect of crotonylation on histones (Jiang et al., 2018). We treated 2D10 cells with NaCr and a submaximal concentration of AZD5582 (1 nM) individually or with a combination of the two drugs for 24 h. Western blot analysis showed that, in whole cell protein lysates, AZD5582 alone effectively reduced cIAP1 and cIAP2 protein levels, leading to lower p100 level and increased p52 level, indicative of cleavage, without impact on other proteins such components of the elongation complex needed for efficient HIV transcription, p-TEFb, the cNF-κB signaling protein RelA, and the autophagy and cell death proteins LC3B, PARP1, and Caspase 3 (Campbell et al., 2018). This differs from a previous report where IAPi alone induced cleavage of Caspase 3 and LC3B, leading to autophagy and/or cell death in memory CD4+ T cells. This may be caused by different responses among cell types studied (Campbell et al., 2018). However, this was consistent with our observations above where no significant cell death was induced by IAPi alone unless in combination with crotonate (Figure 4).

Combination treatment trended toward increased p100 gene expression, although not significantly, compared with LRA treatment alone (Figure 4A). [Gene expression of p100 in 2D10 cells model of HIV latency, related to Figure 5A]. There was no significantly enhanced induction of ACSS2, the enzyme essential for protein crotonylation that plays a direct role in HIV latency reversal (Jiang et al., 2018). This suggested that the synergy observed between AZD8852 and crotonate may not occur solely through direct enhancement of crotonylation activity. As we reported previously in latency models of J-Lat A1 cells and primary CD4+ T cells (Jiang et al., 2018), the addition of crotonate enhanced ACSS2 protein expression in 2D10 cells (Figure 5B). Notably, when AZD5582 and NaCr were administered in combination, the p52 band was greatly enhanced. This suggests an effect of crotonate on the conversion of p100 to p52, enhancing ncNF-κB signaling. A similar enhancement of p52 levels was observed in J-Lat 10.6 and J-Lat A1 cell models of latency where combination treatment of AZD5582 with crotonate enhanced p52 levels (Figure 5C).

Figure 3. Latency reversal by IAPi with distinct chemical structures
(A) 2D10, J-Lat A1 and U1 cells were treated with different doses of AZD5582 (AZD) or Birinapant for 24 h. Percentage of GFP positive in 2D10 and J Lat A1 cells was analyzed by flow cytometry, whereas HIV RNA in U1 cells was analyzed by qPCR (n = 3). *, p < 0.05; **, p < 0.01; ***, p < 0.001, compared with control treatment and analyzed by two-tailed T test. Data are represented as mean ± SEM.
(B) 2D10, J-Lat A1, and U1 cells were treated with 10 nM IAPi, 40 mM NaCr, or their combination for 24 h. Percentage of GFP positive cells in 2D10 and J Lat A1 was analyzed by flow cytometry, whereas HIV RNA in U1 cells was analyzed by qPCR (n = 3). **, p < 0.01; ***, p < 0.001, analyzed by two-tailed T test. Data are represented as mean ± SEM.
Surprisingly, in U1 cells, no significant enhancement in cleavage of p100 was seen when U1 cells were treated in combination, whereas NaCr alone appeared to induce p100 cleavage (Figure 5C). In the primary CD4+ T cell model of latency, even though the combination treatment reduced p100 protein levels, p52 level was not increased. This could be because of the fact that p52 stability is impaired even when p100 cleavage was enhanced in this primary CD4+ T cell model of latency, which may hamper optimal induction of HIV transcription from latency by IAPi (Figure 5C). To further explore the mechanism as to why combination treatment failed to boost p52 levels even though HIV transcription was enhanced in U1 cells, we assessed whether nuclear p52 was enhanced by crotonylation in U1 cells. When U1 cells were fractionated, no increase of p52 production was observed either in the nucleus or in the cytoplasm after AZD5582/NaCr treatment. In contrast, in 2D10 cells, AZD5582 alone induced p52 production which was further augmented by combination treatment in both the nucleus and cytoplasm (Figure 5D). These data indicate that the response of the promonocytic cell line U1 to crotonate/AZD5582 may differ from CD4+ T cells.

Crotonate sensitizes IAPi-induced ncNF-κB reactivation of resting CD4+ T cells isolated from ART-suppressed individuals ex vivo
Although it is difficult to study LRA activity in the resting CD4+ T cells from HIV-infected, ART-treated, and aviremic donors, this is the most relevant system for ex vivo validation. Therefore, we tested whether crotonate enhances cell-associated HIV RNA expression in such cells induced by AZD5582 (Table 1, n = 7).
**Figure 5. Crotonylation stimulated p100 cleavage into p52 in ncNF-κB pathway in CD4+ T cells**

(A) Model of ncNF-κB signaling pathway and the site of action of IAPi/SMACm.

(B) 2D10 cells were treated with 1 nM AZD5582 (AZD), 40 mM NaCr or their combination. Cells were harvested 24 h posttreatment and total proteins were prepared for Western blot.

(C) J-Lat A1 cells were treated with 1 nM AZD, 40 mM NaCr or their combination. U1 cells were treated with 5 nM AZD, or 20 mM NaCr or their combination while J-Lat 10.6 cells were treated with 10 nM AZD, or 40 mM NaCr or their combination. Primary CD4+ T cells were treated with 100 nM AZD, or 30 mM NaCr or their combination. Cells were harvested 24 h posttreatment and total proteins were prepared for the examination of p100/52 protein cleavage by Western blot.

(D) U1 or 2D10 cells were treated as in (C). Then, nucleus and cytoplasm were fractionated and subjected for Western blot analysis, where actin and β-TrCP served as cytoplasmic protein controls and HADC1 or TRIM27 served as nuclear protein controls. Data are represented as mean ± SEM.

Resting CD4+ T cells were treated with 30 mM NaCr, 100 nM AZD5582, or with the combination of 30 mM NaCr and 100 nM AZD5582. The cells were collected 24 and 48 h posttreatment and cell-associated HIV gag RNA expression was measured. We found that either the induction of crotonylation by NaCr or the activation of ncNF-κB signaling by IAPi AZD5582 alone was able to disrupt latent HIV in resting CD4+ T cells, which was consistent with our previous observations (Jiang et al., 2018; Nixon et al., 2020). Importantly, the combination of crotonylation induction by NaCr and ncNF-κB activation by AZD5582 enhanced latency reversal, compared to AZD5582 induction alone (t test, p < 0.05). The induction of cellular toxicity was assessed in primary HIV negative CD4 T cells from additional donors, and was minimal: 5% reduction in viability in AZD5582 alone vs 8% in cells with combination treatment where overall apoptosis was <1.6% (Figures 6 and S5. [Cellular viability in primary CD4+ T cell], related to Figure 6). Enhancement of HIV production by combination treatment was more pronounced 24 h posttreatment. Indeed, the fold induction of HIV transcription achieved significant 24 h, but not 48 h, posttreatment compared with AZD5582 treatment alone (Figures 6C and 6D). This ex vivo evidence supports the idea that crotonylation induction enhances HIV transcription or latency reversal elicited by IAPi-activated ncNF-κB signaling.

**LC MS/MS and GO enrichment analysis of protein crotonylome in latent and reactivated cells**

To understand how protein crotonylation enhances ncNF-κB signaling, we performed a quantitative proteomic analysis of proteins isolated by anti-pan-crotonyl-Lysine antibodies from whole 2D10 cell lysates. Cells were untreated or treated with crotonate for 6 h (Figures 7A–7C). We reasoned that a shorter exposure of crotonate to cells will reduce the indirect and secondary impact triggered by crotonate-induced cellular metabolism. A total of 339 proteins were identified, among them 258 proteins were characterized with more than two unique peptides. In control and NaCr-treated cells, 45 proteins were differentially immunoprecipitated (Figure 7D); 6 proteins were isolated from untreated cells and 39 proteins were from NaCr-treated cells. Overall, 19 crotonylated proteins were identified, which contained 26 direct
crotonylation sites. GO Enrichment analysis indicated that, in NaCr-treated cells, almost all proteins were involved in gene transcription and posttranscriptional regulation, such as mRNA processing, splicing, and maturation (Figure S6 [Pathway analysis of crotonylome], related to Figure 7). Differentially immunoprecipitated proteins in untreated cells compared to NaCr-treated cells were related to the TCA cycle and acyl-CoA metabolism, apart from one protein, TRIM27. Although not directly crotonylated, TRIM27, an E3 ubiquitin ligase, was of special interest as the ubiquitination pathway is essential for the cleavage of p100 into p52 in the ncNF-κB pathway.

**TRIM27 siRNA knockdown decreases HIV transcription at the step of p100/p52 cleavage**

It has been reported that TRIM27, an E3 ubiquitin ligase, is involved in viral replication, alone or with its deubiquitination partner protein USP7 (Zheng et al., 2019). For example, TRIM27 upregulates replication of HCV by suppressing type I interferon response (Zheng et al., 2019). In contrast, when complexed with USP7, TRIM27 can also act as a negative regulator in antiviral signaling (Cai et al., 2018; Hao et al., 2015). To investigate the role of TRIM27 in the regulation of ncNF-κB signaling during latency reversal, TRIM27 was depleted in 2D10 cells using specific siRNAs (Figures 8A and 8B) (Bronevetsky et al., 2016). This caused a significant reduction in the latency reversal induced by the ncNF-κB inducer AZD5582 (Figure 8C). Notably, following IAPi exposure, both p100 and p52 were absent in the TRIM27 siRNA condition (Figure 8B) without significant impact in p100 gene expression (Figure S7. [The impact of TRIM27 siRNA knockdown in p100 gene expression], related to Figure 8). Interestingly, in the basal condition (absence of IAPi treatment), knockdown of TRIM27 slightly reduced p100 levels without impact in the production of p52 (Figure S7. [The impact of TRIM27 siRNA knockdown in p100 gene expression], related to Figure 8), indicating that TRIM27 may largely affect ncNF-κB p100/p52 cleavage machinery when it has been assembled and activated. Knockdown TRIM27 in the primary CD4+ T cell model of latency also reduced p100/p52 protein levels and significantly dampened NaCr-induced HIV latency reversal (Figures 8D–8F), indicating that TRIM27 may play a role in ncNF-κB-dependent HIV transcription. Taken together, these data suggest that TRIM27 may play a role in ncNF-κB signaling through the regulation of p100/p52 cleavage step.

**TRIM27 and USP7 physically and functionally interact with each other in T cells**

The interaction of TRIM27 with the deubiquitinase USP7 maintains TRIM27 stability and its E3 ligase activity (Cai et al., 2018). To study this system in the context of HIV latency reversal, we performed a co-immunoprecipitation analysis with the whole cell protein lysate from 2D10 cells. Cells were treated with AZD5582, NaCr along or with the combination of the two compounds for 24 h. Our data showed that TRIM27 immunoprecipitated with USP7, indicating that they are in the same complex, consistent with reports in other systems (Hao et al., 2015) (Figure 9A). Small molecules to directly inhibit USP7 deubiquitinases are under development as a pharmacologic intervention in many diseases (Li and Liu, 2020). To test whether USP7/TRIM27 complex functionally affects HIV latency reversal, 2D10 cells were treated with the USP7 deubiquitinase inhibitor (USP7i) P5091, which suppresses USP7 deubiquitinase activity, and therefore should destabilize the TRIM27 protein. We found that USP7i potently suppressed the induction of HIV by the combination of NaCr and AZD5582 (Figure 9B). When further analyzed by Western blot, we found that the inhibition of USP7 by P5091 in AZD/NaCr-treated cells partially reduced TRIM27 protein. Surprisingly, NaCr seemed to slightly enhance TRIM27 protein levels. However, the underlying mechanism is not clear and
warrants further investigation because it may be related to crotonylation function. Similar to the impact of TRIM27 siRNA knockdown (Figure 8C), USP7i also reduced both p100 and p52 protein levels (Figure 9C), leading to the reduced latency reversal. These observations further suggest that TRIM27, in the complex with USP7, contributes to HIV transcription by enhancing AZD5582-induced p100 cleavage into p52 possibly via stabilizing both p100 and p52 proteins, thereby stimulating ncNF-κB signaling to disrupt latent HIV.

DISCUSSION

A major obstacle for the clearance of HIV infection, cellular reservoirs of latent virus, cannot be purged by current ART (Archin et al., 2014; Margolis et al., 2020; Sengupta and Siliciano, 2018). Studies in the last decades have expanded our understanding of how HIV latency is established (Jiang and Dandekar, 2015; Margolis et al., 2020; Sengupta and Siliciano, 2018). Strategies to purge the HIV reservoir have been proposed and are being tested in preclinical and clinical studies (Archin et al., 2014; Margolis et al., 2020; Sengupta and Siliciano, 2018). It has become clear that HIV latency is controlled by multiple layers of regulation (Archin et al., 2014; Cary et al., 2016; Jiang and Dandekar, 2015; Margolis et al., 2020; Sengupta and Siliciano, 2018), and that strategies that target a single mechanism of latency regulation thus far cannot broadly or potently disrupt latent HIV across infected cell populations, and may fail to induce sufficient viral antigen to allow for immune clearance.
In this report, we found that crotonylation enhances IAPi-induced ncNF-κB signaling to disrupt HIV latency. In addition to the known effects of crotonylation on histones at the HIV LTR, enhanced processing of p100 to p52 in the ncNF-κB pathway is mediated by crotonylation, and/or a downstream effect of crotonylation, leading to synergistic HIV LTR induction. Quantitative proteomic analyses and biochemical assays suggest that the E3 ubiquitination ligase TRIM27 may be involved in this enhancement at the p100 cleavage step. As the induction of ncNF-κB signaling shows promise in reactivating latent HIV in vivo (Nixon et al., 2020), the strategy to enhance ncNF-κB-mediated latency reversal by crotonylation provides an additional tool for a robust disruption of latent HIV for HIV cure. This warrants further investigation in the future.

It is interesting that the activity of IAPi may also be related to cell type as the promonocytic U1 cell model of latency appears to be less sensitive to IAPi, even at high concentrations (Figures 3 and 5). Other approaches may be required to effectively reverse latency in this model. However, crotonate alone induced an unexpectedly efficient cleavage of p100 into p52 in the U1 model of latency. These observations suggest that ncNF-κB signaling may regulate HIV transcription differently across cell types, whereas crotonylation seems to be involved in ncNF-κB activation in U1 cells. Even though IAPi alone was unable to effectively induce HIV transcription in U1 cells, latent HIV can be disrupted when in combination with crotonylation (Figure 3). This supports the concept that the combination of crotonylation with ncNF-κB induction may be advantageous in latency reversal (Figure 3C).

IAPis also have the potential to induce apoptosis of HIV-infected cells. In both Jurkat and primary CD4+ T cell models of latency, we were unable to see a significant apoptosis induction by IAPi treatment alone, despite effective latency reversal. This differed from previous observations (Campbell et al., 2018), perhaps because of the cell models studied. Interestingly, crotonylation in combination with Birinapant, but not in combination with AZD5582, induced a modest degree of cell death in cells that also expressed HIV.
LTR-driven genes in the Jurkat model of latency (Figure 4), indicating that directly inducing cell death by IAPi is achievable but complex and incompletely understood.

The discovery of TRIM27 as a potential candidate participating in ncNF-κB activation is unexpected. This was supported by the observations that knockdown of TRIM27 reduced HIV transcription and impaired the production of p100/p52 (Figure 8). However, TRIM27 knockdown did not completely dampen AZD5582-induced latency reversal, this may be because of the incomplete TRIM27 knockdown or small molecule AZD5582 may trigger other signaling pathways related to HIV transcription, but currently not discovered. Considering that TRIM27 is primarily a nuclear protein (Figure 5D), TRIM27 may be particularly involved in stabilizing p52 in the nucleus. Interestingly, TRIM27 is often complexed with the deubiquitinase protein USP7 (Cai et al., 2018). This maintains TRIM27 E3 ligase activity by suppression of TRIM27 auto-ubiquitination. However, it is unclear whether this is involved in the transcription of HIV in CD4+ T cells during its regulation of ncNF-κB signaling. Nevertheless, inhibition of USP7 by its pharmacologic inhibitor P5091 abrogated NaCr/AZD-induced latency disruption and impaired p52 stability. This supports the hypothesis that TRIM27, in the complex with USP7, regulates HIV transcription (Figures 9B and 9C). Whether protein crotonylation is directly involved in TRIM27-associated ncNF-κB signaling remains to be determined. Considering that TRIM27 is an E3 ligase, how knockdown of TRIM27 impaired p52 stability (or p100) is not understood. Crotonylation and/or TRIM27 may further regulate the well-described p100 processing via the SCF ubiquitin ligase β-TRCP complex. Inhibition of USP7 is under development as a pharmacologic target for cancer therapy (Li and Liu, 2020). It is possible that USP7 can be further exploited as part of the “lock and block” strategy for HIV cure by impairment of the function of TRIM27 and inhibition of ncNF-κB signaling to enforce latency.

Taken together, we find that crotonate enhances IAPi-induced ncNF-κB signaling to disrupt latency. This was possibly controlled by TRIM27 ubiquitination signaling pathway at the step of p100 cleavage into p52, in addition to the epigenetic regulation of HIV transcription at the HIV LTR (Jiang et al., 2018). These findings provide a deep understanding of the complexity of NF-κB signaling during HIV transcription and the establishment of HIV latency (Wong and Jiang, 2021; Yang et al., 2020), which will help us design alternative tools to deplete stable HIV reservoirs in future.

Limitations of the study
In this study, we have tested several models of HIV latency, including Jurkat models, primary CD4+ T cell models and resting CD4+ T cells isolated from ART-suppressed PLWH, to study the impact of crotonylation...
in the enhancement of AZD5582-induced latency reversal and the activation of ncNF-κB signaling. Although in general crotonate enhanced AZD5582-induced latency reversal, no enhancement was observed in U1 cells. In fact, crotonate alone induced high levels of p52, indicating that crotonylation may be indirectly involved in ncNF-κB activation. However, this was not tested in the other macrophage model of latency, because of the lack of appropriate macrophage-derived latent models. In the primary CD4+ T cell models, we also observed some different degrees of latency enhancement induced by crotonate when different sources of donors were used. This was highlighted by the decreased p100 levels but no enhancement of p52 (Figure 4C), indicating that although crotonylation slightly induces p100 cleavage, p52 is not stable enough to further boost latency reversal. It may be important to stabilize p52 in order to achieve a robust HIV transcription from latency in primary CD4 T cells. In addition, latency reversal might be further improved when the cells are treated longer with IAPi and NaCr or with IAPi because it is well-known that ncNF-κB signaling is slow but persistent compared with cNF-κB activation (Sun, 2012, 2017). These interesting and important observations further highlight the complexity of HIV transcription machinery and HIV latency, which provide us useful information to deepen our understanding of HIV latency and the cure of HIV in future.

STAR+ METHODS
Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- RESOURCE AVAILABILITY
  - Lead contact
  - Materials availability
  - Data and code availability
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
  - Cell models
Primary CD4+ T cell isolation and cell-associated HIV gag RNA measurements
- Immunoblot analysis
- HIV gene expression by real-time PCR analysis or GFP flow cytometry
- Gene knockdown by small interfering RNA
- Co-immunoprecipitation
- Sample preparation for quantitative proteomic analysis
- Mass spectrometry analysis
- MS data analysis

QUANTIFICATION AND STATISTICAL ANALYSIS
- Bliss independent analysis
- Other statistical analyses

SUPPLEMENTAL INFORMATION
Supplemental information can be found online at https://doi.org/10.1016/j.isci.2021.103649.

ACKNOWLEDGMENTS
We thank Dr. Richard Dunham for his critical reading and insightful suggestions and Dr. Jonathan Karn for his 2D10 model of latency. We also thank the participants who donated samples for this study. This work was supported by Qura Therapeutics (2019-01) to GJ, NIH 1R01AI143381-01A1 to EPB, NIH R01 GM133107-01 and R21 AG071229-01 to XC, and Delaney Collaboratory for AIDS Eradication (CARE) UM1AI126619 to DMM.

AUTHOR CONTRIBUTIONS
GJ conceived the study. DL, LMW, YT performed the experiments in latency models in vitro and ex vivo. MGD, SDF, and NMA performed latency reversal analysis in resting CD4+ T cells isolated from PLWH ex vivo. LW and XC performed proteomic analysis. EPB established a primary CD4+ T cell model of latency. DMM provided scientific advice. DJ and GJ assembled the data and wrote the manuscript. All authors read and revised multiple versions of initial writing and approved the manuscript.

DECLARATION OF INTERESTS
GJ has a related patent application (Publication number: 20,200,268,856). Other authors declare no conflict of interest.

Received: July 19, 2021
Revised: November 8, 2021
Accepted: December 15, 2021
Published: January 21, 2022

REFERENCES
Archin, N.M., Liberty, A.L., Kashuba, A.D., Choudhary, S.K., Kuruc, J.D., Crooks, A.M., Parker, D.C., Anderson, E.M., Kearney, M.F., Strain, M.C., et al. (2012). Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487, 482–485.

Archin, N.M., Sung, J.M., Garrido, C., Soriano-Sarabia, N., and Margolis, D.M. (2014). Eradicating HIV-1 infection: seeking to clear a persistent pathogen. Nat. Rev. Microbiol. 12, 750–764.

Banerjee, C., Archin, N., Michaels, D., Belkina, A.C., Denis, G.V., Bradner, J., Sebastiani, P., Margolis, D.M., and Montano, M. (2012). BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. J. Leukoc. Biol. 92, 1147–1154.

Bradley, T., Ferrari, G., Haynes, B.F., Margolis, D.M., and Browne, E.P. (2018). Single-cell analysis of quiescent HIV infection reveals host transcriptional Profiles that regulate proviral latency. Cell Rep. 25, 107–117 e3.

Bronevetsky, Y., Burt, T.D., and McCune, J.M. (2016). Lin28b regulates fetal regulatory T cell differentiation through modulation of TGF-beta signaling. J. Immunol. 197, 4344–4350.

Cai, J., Chen, H.Y., Peng, S.J., Meng, J.L., Wang, Y., Zhou, Y., Qian, X.P., Sun, Y.Y., Pang, X.W., Zhang, Y., et al. (2018). USP7-TRIM27 axis negatively modulates antiviral type I IFN signaling. PNAS 115, 5238–5249.

Campbell, G.R., Bruckman, R.S., Chu, Y.L., Trout, R.N., and Spector, S.A. (2018). SMAC mimetics induce autophagy-dependent apoptosis of HIV-1-infected resting memory CD4+ T cells. Cell Host Microbe 24, 689–702 e687.

Cary, D.C., Fujinaga, K., and Peterlin, B.M. (2016). Molecular mechanisms of HIV latency. J. Clin. Invest. 126, 448–454.

Chun, T.W., Stuyver, L., Mizell, S.B., Ehler, L.A., Mican, J.A., Baseler, M., Lloyd, A.L., Nowak, M.A., and Fauci, A.S. (1997). Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. U S A 94, 13193–13197.

Condon, S.M., Mitsuuchi, Y., Deng, Y., LaPorte, M.G., Rippin, S.R., Haimovitz, T., Alexander, M.D., Kumar, P.T., Hendi, M.S., Lee, Y.H., et al. (2014). Birinapant, a smac-mimetic with improved tolerability for the treatment of solid tumors and hematological malignancies. J. Med. Chem. 57, 3666–3677.

Darcis, G., Kula, A., Bouchat, S., Fujinaga, K., Corazza, F., Ait-Ammar, A., Delacourt, N., Melard, A., Kabeya, K., Vanhulle, C., et al. (2015).
An in-depth comparison of latency-reversing agent combinations in various in vitro and ex vivo HIV-1 latency models identified bryostatin-1+JQ1 and ingenol-8+JQ1 to potently reactivate viral gene expression. PLoS Pathog. 11, e1005066.

Jiang, G., Nguyen, D., Arhin, N.M., Yukl, S.A., Mendez-Lagares, G., Tang, Y., Elsheikh, M.M., Thompson, G.R., 3rd, Hartigan-O'Connor, D.J., Margolis, D.M., et al. (2018). HIV latency is reversed by AC522-driven histone crotonylation. J. Clin. Invest. 128, 1190–1198.

Jiang, G., Maverakis, E., Cheng, M.Y., Elsheikh, M.M., Mende, C., Le, Y.H., Fountain, M.D., Jr., Fon Tacer, K., Xia, H., Pacheco, L., Dutra, M.S., Spivak, A.M., Marlett, J.M., Murry, J.P., Hwang, Y., Maestre, A.M., Manganaro, L., Vamos, M., Teriete, P., et al. (2015). BIRC2/cIAP1 is a negative regulator of HIV-1 transcription and can be targeted by smac mimetics to promote reversal of viral latency. Cell Host Microbe 18, 345–353.

Pearson, R., Kim, Y.K., Hokeljio, J., Lassen, K., Friedmann, J., Tyagi, M., and Karn, J. (2008). Epigenetic silencing of human immunodeficiency virus (HIV) transcription by formation of restrictive chromatin structures at the viral long terminal repeat drives the progressive entry of HIV into latency. J. Virol. 82, 12291–12303.

Sengupta, S., and Siliciano, R.F. (2018). Targeting the latent reservoir for HIV-1. Immunity 48, 872–895.

Sloane, J.L., Benner, N.L., Keenan, K.N., Zang, X., Soliman, M.S.A., Wu, X., Dimapaasoc, M., Chun, T.W., Marsden, M.D., Zack, J.A., et al. (2020). Prodrugs of PKC modulators show enhanced HIV latency reversal and an expanded therapeutic window. Proc. Natl. Acad. Sci. U.S.A 117, 10688–10698.

Spina, C.A., Anderson, J., Archin, N.M., Bosque, A., Chan, J., Famiglietti, M., Greene, W.C., Kushaba, A., Lewin, S.R., Margolis, D.M., et al. (2013). An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients. PLoS Pathog. 9, e1003834.

Sun, S.C. (2012). The non-canonical NF-kappaB pathway. Immunol. Rev. 246, 125–140.

Sun, S.C. (2017). The non-canonical NF-kappaB pathway in immunity and inflammation. Nat. Rev. Immunol. 17, 545–558.

Sun, S.C., and Ley, S.C. (2008). New insights into NF-kappaB regulation and function. Trends Immunol. 29, 469–478.

Wong, L.M., and Jiang, G. (2021). NF-kappaB sub-pathways and HIV cure: a revisit. EBioMedicine 63, 103159.

Wong, J.K., Hezareh, M., Gunthard, H.F., Havlir, D.V., Ignacio, C.C., Spina, C.A., and Richman, D.D. (1997). Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278, 1291–1295.

Yang, X., Wang, Y., Lu, P., Shen, Y., Zhao, X., Zhu, Y., Jiang, Z., Yang, H., Pan, H., Zhao, L., et al. (2020). PEBP1 suppresses HIV transcription and induces latency by inactivating MAPK/NF-kappaB signaling. EMBO Rep. 21, e49305.

Yukl, S.A., Kaiser, P., Kim, P., Telwatte, S., Joshi, S.K., Vu, M., Lampiris, H., and Wong, J.K. (2018). HIV latency in isolated patient CD4+ T cells may be due to blocks in HIV transcriptional elongation, completion, and splicing. Sci Transl Med 10, eaap9927.

Zheng, F., Xu, N., and Zhang, Y. (2019). TRIM27 Promotes hepatitis C virus replication by suppressing type I interferon response. Inflammation 42, 1317–1325.

An in-depth comparison of latency-reversing agent combinations in various in vitro and ex vivo HIV-1 latency models identified bryostatin-1+JQ1 and ingenol-8+JQ1 to potently reactivate viral gene expression. PLoS Pathog. 11, e1005066.

Jiang, G., Nguyen, D., Arhin, N.M., Yukl, S.A., Mendez-Lagares, G., Tang, Y., Elsheikh, M.M., Thompson, G.R., 3rd, Hartigan-O'Connor, D.J., Margolis, D.M., et al. (2018). HIV latency is reversed by AC522-driven histone crotonylation. J. Clin. Invest. 128, 1190–1198.

Jiang, G., Maverakis, E., Cheng, M.Y., Elsheikh, M.M., Mende, C., Le, Y.H., Fountain, M.D., Jr., Fon Tacer, K., Xia, H., Pacheco, L., Dutra, M.S., Spivak, A.M., Marlett, J.M., Murry, J.P., Hwang, Y., Maestre, A.M., Manganaro, L., Vamos, M., Teriete, P., et al. (2015). BIRC2/cIAP1 is a negative regulator of HIV-1 transcription and can be targeted by smac mimetics to promote reversal of viral latency. Cell Host Microbe 18, 345–353.

Pearson, R., Kim, Y.K., Hokeljio, J., Lassen, K., Friedmann, J., Tyagi, M., and Karn, J. (2008). Epigenetic silencing of human immunodeficiency virus (HIV) transcription by formation of restrictive chromatin structures at the viral long terminal repeat drives the progressive entry of HIV into latency. J. Virol. 82, 12291–12303.

Sengupta, S., and Siliciano, R.F. (2018). Targeting the latent reservoir for HIV-1. Immunity 48, 872–895.

Sloane, J.L., Benner, N.L., Keenan, K.N., Zang, X., Soliman, M.S.A., Wu, X., Dimapaasoc, M., Chun, T.W., Marsden, M.D., Zack, J.A., et al. (2020). Prodrugs of PKC modulators show enhanced HIV latency reversal and an expanded therapeutic window. Proc. Natl. Acad. Sci. U S A 117, 10688–10698.

Spina, C.A., Anderson, J., Archin, N.M., Bosque, A., Chan, J., Famiglietti, M., Greene, W.C., Kushaba, A., Lewin, S.R., Margolis, D.M., et al. (2013). An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients. PLoS Pathog. 9, e1003834.

Sun, S.C. (2012). The non-canonical NF-kappaB pathway. Immunol. Rev. 246, 125–140.

Sun, S.C. (2017). The non-canonical NF-kappaB pathway in immunity and inflammation. Nat. Rev. Immunol. 17, 545–558.

Sun, S.C., and Ley, S.C. (2008). New insights into NF-kappaB regulation and function. Trends Immunol. 29, 469–478.

Wong, L.M., and Jiang, G. (2021). NF-kappaB sub-pathways and HIV cure: a revisit. EBioMedicine 63, 103159.

Wong, J.K., Hezareh, M., Gunthard, H.F., Havlir, D.V., Ignacio, C.C., Spina, C.A., and Richman, D.D. (1997). Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278, 1291–1295.

Yang, X., Wang, Y., Lu, P., Shen, Y., Zhao, X., Zhu, Y., Jiang, Z., Yang, H., Pan, H., Zhao, L., et al. (2020). PEBP1 suppresses HIV transcription and induces latency by inactivating MAPK/NF-kappaB signaling. EMBO Rep. 21, e49305.

Yukl, S.A., Kaiser, P., Kim, P., Telwatte, S., Joshi, S.K., Vu, M., Lampiris, H., and Wong, J.K. (2018). HIV latency in isolated patient CD4+ T cells may be due to blocks in HIV transcriptional elongation, completion, and splicing. Sci Transl Med 10, eaap9927.

Zheng, F., Xu, N., and Zhang, Y. (2019). TRIM27 Promotes hepatitis C virus replication by suppressing type I interferon response. Inflammation 42, 1317–1325.
### KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| **Antibodies**      |        |            |
| anti-cIAP1          | abcam  | Cat#ab108361 |
| anti-cIAP2          | abcam  | Cat#ab23423 |
| anti-USP7           | Bethyl | Cat#A700-072 |
| anti-p100/S2        | Cell signaling | Cat#3017 |
| anti-XIAP           | Cell signaling | Cat#14334 |
| anti-NF-κB/p65      | Cell signaling | Cat#4764 |
| anti-NIK            | Cell signaling | Cat#4994 |
| anti-CDK9           | Cell signaling | Cat#2316 |
| anti-pCDK9 (Thr186) | Cell signaling | Cat#2549 |
| anti-PARP1          | Cell signaling | Cat#9542 |
| anti-Cyclin T1      | Cell signaling | Cat#3017 |
| anti-RelB           | Cell signaling | Cat#10544 |
| anti-AceS1 (ACSS2)  | Cell signaling | Cat#81464 |
| anti-β-TrCP         | Cell signaling | Cat#11984 |
| anti-β-actin        | Cell signaling | Cat#4970 |
| anti-Caspase-3      | Cell signaling | Cat#9662 |
| normal rabbit IgG   | Cell signaling | Cat#2729 |
| anti-LC3B           | Invitrogen | Cat#L10382 |
| anti-Trim27         | MyBiosource | Cat#MBS1492534 |
| anti-Pan crotonylLysine | PTM Biolabs | Cat#PTM-S15RM |
| **Biological samples** |        |            |
| Leukapheresis from HIV-infected individuals | University of North Carolina Hospital | N/A |
| **Chemicals, peptides, and recombinant proteins** |        |            |
| AZD5582             | ChemieTek | CT-A5582 |
| Crotonate acid      | Sigma   | 113018-500G |
| **Critical commercial assays** |        |            |
| NE-PER™ Nuclear and Cytoplasmic Extraction Reagents | Thermo Scientific | Cat#78835 |
| NP40 cell lysis Buffer | Invitrogen | Cat#FNN0021 |
| Protease Inhibitor Cocktail powder | Millipore Sigma | Cat#P5714 |
| Protease/Phosphatase Inhibitor Cocktail (100X) | Cell signaling | Cat#S872 |
| RNeasy mini kit     | Qiagen  | Cat#74106 |
| DNase I             | Invitrogen | Cat#18047019 |
| SuperScript™ III Reverse Transcriptase | Invitrogen | Cat#18080093 |
| TaqMan™ Universal PCR Master Mix | ABI | Cat#4304437 |
| Accell Delivery Media | horizon | Cat ID:B-005000-100 |
| Pierce™ Protein A/G Agarose | Thermo Scientific | Cat#20421 |
| EasySep™ Human CD4+ T Cell Enrichment Kit | Stemcell Tech. | Cat#19052 |
| Custom EasySep™ Human Resting CD4+ T Cell Isolation Kit | Stemcell Tech. | N/A |

(Continued on next page)
**RESOURCE AVAILABILITY**

**Lead contact**

Further information and requests for resources and reagents should be directed to the Lead Contact, Dr. Guochun Jiang (Guochun_Jiang@med.unc.edu). This study did not generate new unique reagents.

**Materials availability**

Materials described in this paper are available for distribution under the Uniform Biological Material Transfer Agreement, which was developed by the NIH to simplify the transfer of biological research materials.

**Data and code availability**

All the data associated with this work have been included in this article. This study did not generate any original code. Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.
EXPERIMENTAL MODEL AND SUBJECT DETAILS

Cell models
2D10, J-Lat A1 cells, J-Lat 10.6 and U1 model of HIV latency were cultured in RPMI 1640 medium with 10% fetal bovine serum (FBS) and 1% penicillin streptomycin (Pen-Strep) in a 37°C incubator containing 5% CO2 (43, 44). J-Lat A1 cells, J-Lat 10.6, or U1 cells were from NIH AIDS Reagents Repository, 2D10 cell model of latency was a gift from Dr. Jonathan Karn (Case Western University, Cleveland, OH), which harbors a single copy of HIV-1pNL4-3 whose genome lacks sequences encoding the majority of the Gag-Pol polyprotein, but encompasses the full-length 5 and 3’ LTRs. It includes a gene encoding the marker protein green fluorescent protein (GFP) replacing Nef protein (Pearson et al., 2008). Primary CD4+ T cell model of latency was also used, which has been described in details (Bradley et al., 2018). Multiple HIV latency models were tested because, as thus far, there is not a single in vitro culture model available that captures all the features of HIV latency in vivo.

Primary CD4+ T cell isolation and cell-associated HIV gag RNA measurements
Leukapheresis samples were collected from HIV-infected individuals receiving suppressive antiretroviral therapy (ART). CD4+ T cells were isolated using the EasySep CD4+ T cells Enrichment Kit or a custom resting CD4+ T cells isolation kit (StemCell Technologies) as previously described (44, 46). The purified CD4+ T cells were plated at a density of 2x10^6 cells and treated with indicated compounds. For the HIV gag RNA measurements in resting CD4+ T cells from ART-suppressed individuals, 3–5 replicates of 2–4 million resting CD4+ T cells per replicate were treated with compounds either for 24 or 48 hours. Cells were harvested, total RNA isolated and Gag HIV RNA measured as previously described after normalized with TBP internal control (Gay et al., 2020).

All participants provided informed consent and the study was approved by the UNC Institutional Review Board. The patient information, including age, gender, CD4+ T cell count, ART regimen and time under ART, have been included in Table 1.

Immunoblot analysis
Whole cell protein extract was prepared with NP40 cell lysis buffer containing proteinase inhibitors and phosphatase inhibitors (Sigma). Nuclear/cytoplasmic protein fractionation was achieved by NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Scientific, cat#, 78835). Protein expression of the canonical or non-canonical NF-κB signaling pathway and other HIV transcription-related pathways were evaluated by immunoblot using the corresponding antibody. Quantitation of protein levels was determined by densitometric scanning (Image Lab Software, Bio-Rad).

HIV gene expression by real-time PCR analysis or GFP flow cytometry
Total RNA was isolated using the RNeasy kit (Qiagen) followed by digestion with DNase I (Invitrogen). First-strand cDNA was synthesized using Superscript III (Invitrogen) with random primers (Invitrogen). Real-time PCR (TaqMan) was performed on an ABI QuantStudio 5 system using primers/probe sets purchased from ABI as previously reported (44, 46), where HIV was amplified with the early gag/long LTR region of HIV. The glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and TBP primers/probe sets were used for control PCR (Applied Biosystems Inc.) HIV (GFP) was quantified by GFP expression using flow cytometry and the data were analyzed using FlowJo Software. Cell viability was evaluated using Live/Dead dye (Life Technologies) during flow cytometry.

Gene knockdown by small interfering RNA
2D10 cells or primary CD4+ T cells were plated in 96-well plates at 1x10^6 cells/ml in Accell Delivery Media (Dharmacon). Accell small interfering RNAs (siRNAs) (E-006552-00-0020, Dharmacon) or its scrambled control siRNAs (D-001910-10-20, Dharmacon) were added to the cells at a final concentration of 1.5 μM. Cells were incubated with siRNA for 2 days. Cells were then re-suspended in RPMI 1640 medium with 10% fetal bovine serum (FBS), 1% penicillin streptomycin (Pen-Strep) and 10% FBS complete with 5 nM AZD5582. Cells were harvested after 24 hours. Then, RNA and protein were isolated.

Co-immunoprecipitation
Immunoprecipitations (IP) were performed as before (Li et al., 2012). Briefly, treated or untreated 2D10 cells were washed and lysed in 150 mM NaCl, 50 mM Tris-HCl (pH 7.2), 0.5% NP-40, and protease inhibitor
cocktail (Cell Signaling) followed by an incubation at 4°C for 20 min with vortex. Clarified lysates were pre-cleared with protein A/G agarose beads (Thermo Scientific), followed by IP with either anti-USP7 monoclonal antibody (Bethyl), anti-TRIM27 polyclonal antibody (MyBioSource), or normal rabbit IgG (Cell Signaling). IP was analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting with 1st antibodies of anti-USP7 or anti-Trim27 antibody and 2nd antibodies of horse-radish peroxidase-conjugated secondary antibody, followed by chemiluminescence detection (Amersham).

Sample preparation for quantitative proteomic analysis
One million of 2D10 cells were treated with or without 30 mM NaCr for 6 hours. Whole cell protein extracts were prepared with RIPA buffer (Sigma) followed by Co-IP with IgG or anti-PanCrotonylLysine antibody (PTM biolabs). The immune-complexes were prepared by Immunoprecipitation Dynabeads Kit and eluted by boiling in 20 µl SDS-PAGE sample buffer at 95°C for 5 minutes. The complex protein were further fractionated on a 10% SDS-PAGE gel and tryptic digested into peptides overnight at 37°C. Three biological replicates were prepared for this experiment.

Mass spectrometry analysis
Peptides were cleaned up by C18 stage tips. The clean peptides were dissolved in 0.1% formic acid and analyzed on a Q-Exactive HF-X coupled with an Easy nanoLC 1200 (Thermo Fisher Scientific, San Jose, CA). 5 µL of peptides were loaded on to an Acclain PepMap RSLC C18 Column (250 mm × 75 µm ID, C18, 2 µm, Thermo-Fisher). Analytical separation of all peptides was achieved with 30 min gradient. A linear gradient of 5 to 30% buffer B over 17 min was executed at a 300 nL/min flow rate followed a ramp to 40% B in 3 min, and 10-min wash with 100% buffer B, where buffer A was aqueous 0.1% formic acid, and buffer B was 80% acetonitrile and 0.1% formic acid.

LC-MS experiments were performed in a data-dependent mode with full MS (externally calibrated to a mass accuracy of <5 ppm and a resolution of 60,000 at m/z 200) followed by high energy collision-activated dissociation-MS/MS of the top 20 most intense ions with a resolution of 15,000 at m/z 200. High energy collision-activated dissociation-MS/MS was used to dissociate peptides at a normalized collision energy of 27 eV in the presence of nitrogen bath gas atoms. Dynamic exclusion was 30.0 seconds. There were two biological replicates for one treatment and each sample was subjected to two technical LC-MS replicates.

MS data analysis
Mass spectra processing and peptide identification were performed on the Andromeda search engine in MaxQuant software (Version 1.6.0.16) against a human UniProt database (UP000005640). All searches were conducted with a defined modification of cysteine carbamidomethylation, with methionine oxidation and protein amino-terminal acetylation as dynamic modifications. Peptides were confidently identified using a target-decoy approach with a peptide false discovery rate (FDR) of 1% and a protein FDR of 1%. A minimum peptide length of 7 amino acids was required, maximally two missed cleavages were allowed, initial mass deviation for precursor ion was up to 7 ppm, and the maximum allowed mass deviation for fragment ions was 0.5 Da. Data processing and statistical analysis were performed on Perseus (Version 1.6.0.7). Protein quantitation was performed on biological replicate runs, and a two-sample T-test statistics was used to report statistically significant expression fold-changes.

QUANTIFICATION AND STATISTICAL ANALYSIS
Bliss independent analysis
Synergy of crotonate with AZD5582 in latency reversal was calculated by the Bliss independence analysis (Jiang et al., 2018; Laird et al., 2015). All the values were normalized with the percentage of GFP+ cells reactivated by PMA. For drugs x and y, the predicted fraction affected by the combination of drug x and drug y (faxyP) is defined as the equation faxyP = fax +fay–(fax)(fay), where the observed values of individual drug x is fax and drug y was fay. The observed combination effect (FaxyO) is the value when both drug x and drug y are tested together. Using this model, Δfaxy = faxyO–faxyP defines the synergy if Δfaxy > 0, additive effect if Δfaxy = 0, or antagonism if Δfaxy < 0. Statistical significance was determined using a two-tailed t-test to compare faxyO with faxyP, where *, p<0.05 was considered significant.
Other statistical analyses
Means and standard errors (SEs) were calculated for all data points from at least 3 independent experiments. Statistical significance was determined using the two-tailed Student T test or One-way ANOVA test, where *, p <0.05 was considered significant. GO functional enrichment was performed by using software tool FunRich (funrich.org).